Actinium Pharmaceuticals (ATNM)
Develops targeted radiotherapies for cancer and transplant conditioning.
Something off on this page? Send us feedback.
Develops targeted radiotherapies and conditioning agents for cancer and transplant or cell/gene therapy, with clinical candidates and a preclinical solid-tumor program. The business remains development-stage: it has no approved products and depends on clinical progress, partners, isotope suppliers, and manufacturing.
Develops targeted cancer therapeutics and transplant-conditioning agents by linking antibodies to radioactive isotopes. The portfolio includes ATNM-400 for solid tumors, Actimab-A for AML/MDS and solid-tumor strategies, and the Iomab-ACT and Iomab-B conditioning programs.
Operates a single research, discovery, and clinical-development segment from New York, with all assets located in the United States. Work spans target selection, radioconjugate design, preclinical and clinical development, isotope and drug-product supply, and clinical-stage manufacturing build-out.
Has no approved products or product-sale revenue. Advancement depends on clinical and regulatory results, strategic partners for key programs, and specialized third parties for isotopes, manufacturing, storage, and distribution while its planned New York facility is not yet operational.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $36.5M · Total debt $1.3M · Total assets $40.2M · Shareholders' equity $30.3M
- Revenue
- $35.0M
- Operating income
- $27.6M
- Net income
- $27.9M
No dividends on record.
| Institutions | 16.83% | 5.29M shares | |
|---|---|---|---|
| 48 holders · as of Jun 30, 2026 | |||
| Insiders | 8.27% | 2.60M shares | |
| 8 holders · as of Sep 10, 2026 | |||
| Strategic holders | 10.55% | 3.32M shares | |
| 2 holders · as of Nov 4, 2024 | |||
| Other | 64.35% | 20.23M shares | |
| remainder | |||
31.44M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Sandesh SethInsiderdirector, officer: Chief Executive Officer | 6.25% | 1.97M | filed Sep 4, 2026 |
BlackRock, Inc.Strategic | 5.38% | 1.69M | filed Jan 29, 2024 |
The Vanguard GroupStrategic | 5.17% | 1.63M | filed Nov 4, 2024 |
Vanguard Capital Management LLCInstitution | 3.94% | 1.24M | as of Jun 30, 2026 |
Compass Financial Management LLCInstitution | 1.91% | 600,230 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Novartis (ADR)
Prostate radioligand leader with a competing actinium-225 program.
- AstraZeneca (ADR)
Ac-225 prostate program and solid-tumor drugs overlap across three arenas.
- Telix Pharmaceuticals
PSMA radioligands contest the prostate-radiotherapy pathway.
- Pfizer
Marketed CD33 ADC is the direct therapeutic benchmark in AML.
- Bristol-Myers Squibb
Ac-225 platform and solid-tumor pipeline compete for RPT capacity.
- Johnson & Johnson
EGFR-directed therapy is a major NSCLC standard-of-care threat.
- Cellectar Biosciences
Radioconjugate platform overlaps in radiotherapy development and supply.
- Perspective Therapeutics
Lead-212 platform competes for alpha-therapy capacity and trial sites.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Actinium Pharmaceuticals | $1.16 | −0.61% | $36.7M | 3.2 | — | 1.0 | — |
| Novartis (ADR) | $142.40 | +0.79% | $268.53B | 21.3 | 15.2 | 4.8 | +0.9% |
| AstraZeneca (ADR) | $165.27 | −1.84% | $261.12B | 25.3 | 15.5 | 4.3 | +6.4% |
| Telix Pharmaceuticals | $11.31 | −5.36% | $4.05B | 121.9 | — | 4.4 | +22.2% |
| Pfizer | $27.92 | −0.05% | $159.19B | 36.9 | 10.0 | 2.5 | +2.6% |
| Bristol-Myers Squibb | $61.63 | −1.00% | $127.16B | 13.7 | 9.6 | 2.6 | +5.7% |
| Johnson & Johnson | $270.08 | +0.33% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| Cellectar Biosciences | $2.23 | 0.00% | $17.8M | — | — | — | — |
| Perspective Therapeutics | $2.59 | −12.67% | $337.6M | — | — | 922.3 | −72.1% |
| Median | 28.2 | 15.2 | 4.4 | +5.7% |